Modalis is a Waltham MA/Tokyo based biotech company developing gene therapies for rare diseases with a novel CRISPR based epigenome editing technology.
Joined August 2019
- Tweets 25
- Following 16
- Followers 80
- Likes 2
12 Photos and videos
May 14
Modalis Receives Donation from Swiss Patient Organization “Emily’s Future is Now”
Let’s fight this disease together !
modalistx.com/donation-from-…
2
12
2,068
25 Dec 2025
Modalis Announces Publication in Human Gene Therapy of Study Demonstrating Efficient LAMA1 Gene Activation for the Treatment of LAMA2-CMD - businesswire.com/news/home/2…
4
257
8 Jun 2025
We are thrilled to announce a strategic partnership with SOLVE FSHD, along with successful strategic funding dedicated to advancing our MDL-103 for the treatment of facioscapulohumeral muscular dystrophy (FSHD).
1
3
1,554
12 May 2025
Modalis has been selected as a finalist in the XPRIZE Healthspan FSHD Bonus Prize Competition and awarded research funds. #xprize
businesswire.com/news/home/2…
2
4
1,856
6 Jan 2025
Happy New Year 2025!
Excited to announce the new chapter of the collaboration!
2
3
3,423
25 Oct 2024
Modalis Therapeutics has received an Orphan Drug Designation from the U.S. Food and Drug Administration for MDL-101, a treatment for congenital muscular dystrophy type 1A (LAMA2-CMD).
1
6
16
5,154
30 Sep 2024
FDA Grants Rare Pediatric Disease Designation to MDL-101 for the treatment of congenital muscular dystrophy type 1a (LAMA2-CMD)
1
4
3,121
27 Sep 2024
MODALIS to present its development progress at the Genome Editing Tx Summit.
1
1,816
24 Jul 2024
Modalis will present process development data at the 16th Annual Bioprocessing Summit on Aug 20th.
1
1
1,209
6 Jul 2024
Our development efforts towards LAMA2-CMD were featured.
lama2.com/news/modlalis-anno…
1
544
7 May 2024
Excited to share that a paper has been published on preclinical data from our lead program, MDL-101 !
businesswire.com/news/home/2…
7
1
880
15 Apr 2024
MODALIS to present MDL-101 data at 4th Next Generation Gene Therapy Vector conference.
1
1
591
12 Apr 2024
Modalis announced our collaboration with Ginkgo Bioworks. Epigenome editing meets Synthetic Biology and the world-leading biofoundry capabilities!
businesswire.com/news/home/2…
1
521
24 Dec 2023
We are excited to announce that MODALIS' mini-Cas9 patent has been granted in Japan.
lnkd.in/gX9tBtjB
1
323
13 Dec 2023
Modalis announced research collaboration with JCR pharma, a rare disease company, on an undisclosed CNS target.
businesswire.com/news/home/2…
1
147
20 Sep 2023
Our scientist, John, is participating as one of the panel for the webinar.
insights.bio/cell-and-gene-t…
103
3 Sep 2023
MODALIS is the sole company to put both ACTIVATION and SUPPRESSION into practical use.
genengnews.com/topics/genome…
1
105
modalis retweeted
20 Apr 2022
2